A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients

J. J. Raizer*, P. Giglio, J. Hu, M. Groves, R. Merrell, C. Conrad, S. Phuphanich, V. K. Puduvalli, M. Loghin, N. Paleologos, Y. Yuan, D. Liu, A. Rademaker, W. K. Yung, B. Vaillant, J. Rudnick, M. Chamberlain, N. Vick, S. Grimm, I. W. Tremont-LukatsJ. De Groot, K. Aldape, M. R. Gilbert

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Fingerprint Dive into the research topics of 'A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients'. Together they form a unique fingerprint.

Medicine & Life Sciences